This study is currently recruiting participants.
Verified December 2012 by Gilead Sciences
This is a multicenter, Open-Label, Randomized Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin Administered for 24 weeks in Patients Infected with Chronic HCV with Cirrhosis and Portal Hypertension with or without Liver Decompensation. Approximately 50 subjects (25 per group) will be randomized (1:1) to either receive study drug for 24 weeks or take part in an untreated observational arm for the first 24 weeks followed by study drug for another 24 weeks.
